4.7 Article

Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data

期刊

JOURNAL OF CLINICAL ONCOLOGY
卷 28, 期 2, 页码 264-271

出版社

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2009.24.0952

关键词

-

类别

向作者/读者索取更多资源

Purpose The sixth edition of American Joint Committee on Cancer (AJCC) Cancer Staging Manual for colon cancer subdivided stage II into IIA (T3N0) and IIB (T4N0) and stage III into IIIA (T1-2N1M0), IIIB (T3-4N1M0), and IIIC (anyTN2M0). Subsequent analyses supported revised substaging of stage III because of improved survival for T1-2N2 versus T3-4N2 and T4N1 survival was more similar to T3-4N2 than to T3N1. The AJCC Hindgut Taskforce sought population-based validation that depth of invasion and nodal status interact to affect survival. Patients and Methods Surveillance, Epidemiology, and End Results (SEER) population-based data from January 1992 to December 2004 for 109,953 colon cancer patients were compared with National Cancer Data Base (NCDB) data on 134,206 patients. T4N0 cancers were stratified by tumors that perforate visceral peritoneum (T4a) versus tumors that invade or are adherent to adjacent organs or structures (T4b). N1 and N2 were stratified by number of involved positive lymph nodes (N+): N1a/N1b (1 v 2-3), N2a/ N2b (4 to 6 v >= 7). Five-year observed and relative survival data were obtained for each TN category. Results SEER colon cancer analyses confirm that patients with T1-2N0 cancers have better survival than T3N0, T3N0 better than T4N0, T1-2N2 better than T3-4N2, and T4bN1 similar to T4N2. Patients with T4a lesions have better survival than T4b by N category. The number of positive nodes affects survival for each T category. Conclusion This SEER population-based colon cancer analysis is highly consistent with rectal cancer pooled analysis and SEER rectal cancer analyses, supporting the shift of T1-2N2 lesions from IIIC to IIIA/IIIB, shifting T4bN1 from IIIB to IIIC, subdividing T4/N1/N2, and revising substaging of stages II/III. Survival outcomes by TN category for colon and rectal cancer are strikingly similar.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

Harry H. Yoon, David Tougeron, Qian Shi, Steven R. Alberts, Michelle R. Mahoney, Garth D. Nelson, Suresh G. Nair, Stephen N. Thibodeau, Richard M. Goldberg, Daniel J. Sargent, Frank A. Sinicrope

CLINICAL CANCER RESEARCH (2014)

Article Oncology

Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial)

Dan Sha, Adam M. Lee, Qian Shi, Steven R. Alberts, Daniel J. Sargent, Frank A. Sinicrope, Robert B. Diasio

CLINICAL CANCER RESEARCH (2014)

Article Oncology

Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147

Jocelin Huang, Suresh G. Nair, Michelle R. Mahoney, Garth D. Nelson, Anthony F. Shields, Emily Chan, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, James T. Quesenberry, Stephen N. Thibodeau, Thomas C. Smyrk, Axel Grothey, Frank A. Sinicrope, Thomas A. Webb, Gist H. Farr, Barbara A. Pockaj, Jeffrey L. Berenberg, Margaret Mooney, Daniel J. Sargent, Steven R. Alberts

CLINICAL COLORECTAL CANCER (2014)

Article Medicine, Research & Experimental

Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment

Ming-Wen An, Sumithra J. Mandrekar, Martin J. Edelman, Daniel J. Sargent

CONTEMPORARY CLINICAL TRIALS (2014)

Article Oncology

The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community

Yan Liu, Saskia Litiere, Elisabeth G. E. de Vries, Daniel Sargent, Lalitha Shankar, Jan Bogaerts, Lesley Seymour

EUROPEAN JOURNAL OF CANCER (2014)

Article Oncology

The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database

Saskia Litiere, Elisabeth G. E. de Vries, Lesley Seymour, Dan Sargent, Lalitha Shankar, Jan Bogaerts

EUROPEAN JOURNAL OF CANCER (2014)

Article Pharmacology & Pharmacy

RANDOMIZED PHASE II CLINICAL TRIALS

Sin-Ho Jung, Daniel J. Sargent

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2014)

Article Oncology

Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse

Sumithra J. Mandrekar, Ming-Wen An, Jeffrey Meyers, Axel Grothey, Jan Bogaerts, Daniel J. Sargent

JOURNAL OF CLINICAL ONCOLOGY (2014)

Article Oncology

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Anna Gonzalez-Neira, Miguel Martin, Daniel Sargent, Erin Green, Howard McLeod, Ulrich M. Zanger, Matthias Schwab, Michael Braun, Matthew Seymour, Lindsay Thompson, Benjamin Lacas, Valerie Boige, Nuria Ribelles, Shoaib Afzal, Henrik Enghusen, Soren Astrup Jensen, Marie-Christine Etienne-Grimaldi, Gerard Milano, Mia Wadelius, Bengt Glimelius, Hans Garmo, Milena Gusella, Thierry Lecomte, Pierre Laurent-Puig, Eva Martinez-Balibrea, Rohini Sharma, Jesus Garcia-Foncillas, Zdenek Kleibl, Alain Morel, Jean-Pierre Pignon, Rachel Midgley, David Kerr, Ian Tomlinson

JOURNAL OF CLINICAL ONCOLOGY (2014)

Article Health Care Sciences & Services

Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials

Jeff A. Sloan, Daniel J. Sargent, Paul J. Novotny, Paul A. Decker, Randolph S. Marks, Heidi Nelson

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)

Article Oncology

Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis

Xavier Paoletti, Koji Oba, Yung-Jue Bang, Harry Bleiberg, Narikazu Boku, Olivier Bouche, Paul Catalano, Nozomu Fuse, Stefan Michiels, Markus Moehler, Satoshi Morita, Yasuo Ohashi, Atsushi Ohtsu, Arnaud Roth, Philippe Rougier, Junichi Sakamoto, Daniel Sargent, Mitsuru Sasako, Kohei Shitara, Peter Thuss-Patience, Eric Van Cutsem, Tomasz Burzykowski, Marc Buyse

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)

Article Multidisciplinary Sciences

Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer

Hanna K. Sanoff, Lindsay A. Renfro, Pradeep Poonnen, Pratibha Ambadwar, Daniel J. Sargent, Richard M. Goldberg, Howard McLeod

PLOS ONE (2014)

Article Mathematical & Computational Biology

Multi-state models for colon cancer recurrence and death with a cured fraction

A. S. C. Conlon, J. M. G. Taylor, D. J. Sargent

STATISTICS IN MEDICINE (2014)

Article Computer Science, Interdisciplinary Applications

Center-within-trial versus trial-level evaluation of surrogate endpoints

L. A. Renfro, Q. Shi, Y. Xue, J. Li, H. Shang, D. J. Sargent

COMPUTATIONAL STATISTICS & DATA ANALYSIS (2014)

Article Oncology

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status

Thierry Andre, Timothy Iveson, Roberto Labianca, Jeffrey A. Meyerhardt, Ioannis Souglakos, Takayuki Yoshino, James Paul, Alberto Sobrero, Julien Taieb, Anthony F. Shields, Atsushi Ohtsu, Axel Grothey, Daniel J. Sargent

CURRENT COLORECTAL CANCER REPORTS (2013)

暂无数据